Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis

Journal of Inherited Metabolic Disease

Volumn 39, Issue 1, 2016, Pages 75-83

  Mignarri, Andrea ^a   Magni, Alessandro ^b   Del Puppo, Marina ^b   Gallus, Gian Nicola ^a   Björkhem, Ingemar ^c   Federico, Antonio ^a   Dotti, Maria Teresa ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; 7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; 7ALPHA HYDROXYCHOLESTEROL; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL; LATHOSTEROL; OXYSTEROL; PHYTOSTEROL; UNCLASSIFIED DRUG; 27-HYDROXYCHOLESTEROL; 7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; BIOLOGICAL MARKER; CHOLEST 4 EN 3 ONE; CHOLESTANOL; CHOLESTEROL DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BILE ACID BLOOD LEVEL; BIOCHEMICAL ANALYSIS; CEREBROTENDINOUS XANTHOMATOSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISORDERS OF CHOLESTEROL METABOLISM; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; BLOOD; DISEASE COURSE; LIPID METABOLISM; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; BILE ACIDS AND SALTS; BIOMARKERS; CHENODEOXYCHOLIC ACID; CHOLESTANOL; CHOLESTENONES; CHOLESTEROL; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; LIPID METABOLISM; MALE; MIDDLE AGED; PROGNOSIS; XANTHOMATOSIS, CEREBROTENDINOUS; YOUNG ADULT;

EID: 84954399626     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-015-9873-1     Document Type: Article

References (43)

1. Alessandrini L, Ciuffreda P, Santaniello E, Terraneo G (2004) Clemmensen reduction of diosgenin and kryptogenin: synthesis of [16,16,22,22,23,23-(2)H(6)]-(25R)-26-hydroxycholesterol. Steroids 69:789–794
2. Ali Z, Heverin M, Olin M et al (2013) On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1(-/-) mice. J Lipid Res 54:1033–1043
3. Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876
4. Båvner A, Shafaati M, Hansson M et al (2010) On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. J Lipid Res 51:2722–2730
5. Berginer VM, Berginer J, Korczyn AD, Tadmor R (1994) Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study. J Neurol Sci 122:102–108
6. Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147
7. Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649–1652
8. Bertolotti M, Del Puppo M, Gabbi C et al (2008) Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids 73:1197–1202
9. Björkhem I (2013) Cerebrotendinous xanthomatosis. Curr Opin Lipidol 24:283–287
10. Björkhem I, Diczfalusy U, Lövgren-Sandblom A et al (2014) On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO. J Lipid Res 55:1165–1172
11. Björkhem I, Hansson M (2010) Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem Biophys Res Commun 396:46–49
12. Cali JJ, Hsieh CL, Francke U et al (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779–7783
13. Camilleri M, Nadeau A, Tremaine WJ et al (2009) Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 21:734–e743
14. Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW (2007) Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab 5:73–79
15. DeBarber AE, Connor WE, Pappu AS, Merkens LS, Steiner RD (2010) ESI-MS/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. Clin Chim Acta 411:43–48
16. de Sain-van der Velden MG, Verrips A, Prinsen BH, de Barse M, Berger R, Visser G (2008) Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX. J Inherit Metab Dis 31:S387–S393
17. De Stefano N, Dotti MT, Mortilla M, Federico A (2001) Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 124:121–131
18. Del Puppo M, Kienle MG, Petroni ML, Crosignani A, Podda M (1998) Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J Lipid Res 39:2477–2482
19. Dzeletovic S, Breuer O, Lund E, Diczfalusy U (1995) Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 225:73–80
20. Ellis E, Axelson M, Abrahamsson A et al (2003) Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38:930–938
21. Fakheri RJ, Javitt NB (2012) 27-Hydroxycholesterol, does it exist? On the nomenclature and stereochemistry of 26-hydroxylated sterols. Steroids 77:575–577
22. Galli Kienle M, Anastasia M, Cighetti G, Galli G, Fiecchi A (1980) Studies on the 14 alpha-demethylation mechanism in cholesterol biosynthesis. Eur J Biochem 110:93–105
23. Ginanneschi F, Mignarri A, Mondelli M et al (2013) Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol 260:268–274
24. Heverin M, Meaney S, Lütjohann D, Diczfalusy U, Wahren J, Björkhem I (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46:1047–1052
25. Inoue K, Kubota S, Seyama Y (1999) Cholestanol induces apoptosis of cerebellar neuronal cells. Biochem Biophys Res Commun 256:198–203
26. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB (1988) Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 29:1149–1155
27. Kuriyama M, Fujiyama J, Kasama T, Osame M (1991) High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis. J Lipid Res 32:223–229
28. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
29. Leoni V, Caccia C (2011) Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 164:515–524
30. Liu J, Lu H, Lu YF et al (2014) Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci 141:538–546
31. Martini G, Mignarri A, Ruvio M et al (2013) Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 92:282–286
32. Mignarri A, Dotti MT, Del Puppo M et al (2012) Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation: six-year MRI follow-up. Neuroradiology 54:649–651
33. Mignarri A, Gallus GN, Dotti MT, Federico A (2014) A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis 37:421–429
34. Mignarri A, Rossi S, Ballerini M et al (2011) Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 258:783–790
35. Panzenboeck U, Andersson U, Hansson M, Sattler W, Meaney S, Björkhem I (2007) On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J Lipid Res 48:1167–1174
36. Pilo de la Fuente B, Jimenez-Escrig A, Lorenzo JR et al (2011a) Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 18:1203–1211
37. Pilo de la Fuente B, Sobrido MJ, Girós M et al (2011b) Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis. Neurologia 26:397–404
38. Rubio-Agusti I, Kojovic M, Edwards MJ et al (2012) Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 27:1769–1774
39. Salen G, Kwiterovich PO Jr, Shefer S et al (1985) Increased plasma cholestanol and 5 alpha-saturated plant sterol derivatives in subjects with sitosterolemia and xanthomatosis. J Lipid Res 26:203–209
40. Van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316
41. van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607
42. Wolthers BG, Walrecht HT, van der Molen JC, Nagel GT, Van Doormaal JJ, Wijnandts PN (1991) Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res 32:603–612
43. Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83